Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating on the company.
Separately, Chardan Capital raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th.
Check Out Our Latest Research Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
